Zobrazeno 1 - 10
of 5 638
pro vyhledávání: '"Hepatitis B surface antigen"'
Autor:
Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background While previous reports have shown that hepatitis B virus (HBV) infection affects lipid metabolism and vice versa, the impact of dyslipidemia on the functional cure of HBV infection following peginterferon alfa (PegIFNα) therapy r
Externí odkaz:
https://doaj.org/article/4a7fabe407e440be93ea1fc33f6319f8
Autor:
Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Ting Zhu, Xiaoxia Li, Yanling Li, Xiaojing Song, Yang Han, Wei Lyu, Wei Cao, Taisheng Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Several studies have reported that combination antiretroviral therapy (cART) enhances the hepatitis B surface antigen (HBsAg) clearance rate in Human Immunodeficiency Virus-1/Hepatitis B Virus (HIV/HBV) coinfected patients, yet th
Externí odkaz:
https://doaj.org/article/adfd764866b3485c804265ba9299c141
Autor:
Lina Wu, Jiadi Lai, Qiumin Luo, Yeqiong Zhang, Chaoshuang Lin, Dongying Xie, Youming Chen, Hong Deng, Zhiliang Gao, Liang Peng, Wenxiong Xu
Publikováno v:
Liver Research, Vol 8, Iss 3, Pp 179-187 (2024)
Background and aim: Few studies have reported hepatitis B surface antigen (HBsAg) kinetics after nucleos(t)ide analog (NA) discontinuation in patients with noncirrhotic chronic hepatitis B (CHB). The study specifically investigated long-term HBsAg ki
Externí odkaz:
https://doaj.org/article/415b38de27784d988b5083a1ef4ab88c
Autor:
Yuying Li, Siqi Yang, Cong Li, Zhenjie Ma, Mengmeng Zhang, Wenhang Zou, Zihao Wu, Haiyan Hou, Weixing Wang, Liying Zhu
Publikováno v:
Virology Journal, Vol 21, Iss 1, Pp 1-9 (2024)
Abstract Purpose Peginterferon alfa-2b (Peg-IFN α-2b) has demonstrated superior efficacy over nucleos(t)ide analogs (NAs) in the treatment of chronic hepatitis B (CHB), particularly among patients with low levels of hepatitis B surface antigen (HBsA
Externí odkaz:
https://doaj.org/article/16deed8fddd645a9b4ee0c28934269ff
Publikováno v:
Nigerian Journal of Paediatrics, Vol 44, Iss 1, Pp 14-21 (2024)
Background: Majority of secondary school students are adolescents; an age group with a tendency to engage in health- compromising risky behaviours in order to deal with anxiety and gain admission to peer groups. This exposes them to risk of Hepatitis
Externí odkaz:
https://doaj.org/article/d47f14e96d8447f3a06e87189885f1bd
Autor:
Anna S. F. Lok
Publikováno v:
Gut and Liver, Vol 18, Iss 4, Pp 593-601 (2024)
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocell
Externí odkaz:
https://doaj.org/article/cf9f566970f640ac8ddce25d7e3a5556
Autor:
Li Yadi, Luo Haiying, Hu Xiaoxia, Gong Jiaojiao, Tan Guili, Luo Huating, Wang Rui, Pang Hao, Yu Renjie, Qin Bo
Publikováno v:
Polish Journal of Microbiology, Vol 73, Iss 2, Pp 217-235 (2024)
Interferon-alpha (IFN-α) is a first-line drug for treating chronic hepatitis B (CHB). Guanylate-binding protein 1 (GBP1) is one of the interferon-stimulating factors, which participates in the innate immunity of the host and plays an antiviral and a
Externí odkaz:
https://doaj.org/article/9dae418c70fe47b6969af8e87be24f0e
Autor:
Shuqin Gu, Libo Tang, Ling Guo, Chunxiu Zhong, Xin Fu, Guofu Ye, Shihong Zhong, Xiaoyi Li, Chunhua Wen, Yang Zhou, Jinling Wei, Haitao Chen, Nikolai Novikov, Simon P. Fletcher, M. Anthony Moody, Jinlin Hou, Yongyin Li
Publikováno v:
Emerging Microbes and Infections, Vol 13, Iss 1 (2024)
It is well established that humoral immunity targeting hepatitis B virus surface antigen (HBsAg) plays a critical role in viral clearance and clinical cure. However, the functional changes in HBsAg-specific B cells before and after achieving function
Externí odkaz:
https://doaj.org/article/f7d734b3c4d9471c9d5b1528dfa1a03e
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Hepatitis B surface antigen (HBsAg) seroclearance is recommended as the ideal endpoint for nucleos(t)ide analog (NA) treatments. Functional cure of chronic hepatitis B (CHB) is defined as having undetectable serum hepatitis B virus (HBV) deoxyribonuc
Externí odkaz:
https://doaj.org/article/d7610805f8d043d7899c0925a944d1ce
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 10 (2024)
ABSTRACT Toll-like receptors (TLRs) play a crucial role in eliminating viral infection. Conversely, viruses have evolved various strategies to disrupt TLR signaling during chronic infection. In the case of hepatitis B virus (HBV), we previously repor
Externí odkaz:
https://doaj.org/article/b2968d2d090e4af1927132d928d6df19